2020 THRIVE GRANT AWARD WINNERS

We are pleased to announce this year’s grant award winners, selected from nearly 80 proposals received from more than 35 different institutions. Each of the winning proposals, listed below, will receive $50,000 in funding to support their research in making cancer patient quality of life an active research priority.

2020 THRIVE Grant Award Winners

HESI THRIVE Research Study: Stop LCNP: High dose steroid therapy for late radiation-associated lower cranial neuropathy

  • Katherine Hutcheson, PhD, Stephen Y. Lai, MD, PhD, and Karin Woodman, MD
  • The University of Texas, MD Anderson Cancer Center
  • This clinical project seeks to use high dose steroid therapy to improve swallowing and speech function in long-term survivors of head and neck cancer (HNC) who have nerve dysfunction as a late side effect of their cancer treatment.

HESI THRIVE Research Study: FMT treatment for immune checkpoint inhibitor–mediated colitis

  • Yinghong Wang, MD, PhD, MSc
  • The University of Texas, MD Anderson Cancer Center
  • This prospective study seeks to use fecal transplantation to reduce immune-mediated colitis (which is currently extremely difficult to treat) in patients with melanoma and genitourinary cancer who are receiving immunosuppressive therapies.

HESI THRIVE Research Study: Targeting complement signaling to ameliorate cranial radiation-induced brain injury

  • Munjal M. Acharya, PhD, Andrea J. Tenner, PhD
  • University of California, Irvine
  • This study seeks to improve long-term outcomes for brain cancer survivors by using a genetically modified mouse model to explore the biological mechanisms associated with chronic, radiation-induced cognitive damage.

HESI THRIVE Research Study: Utilization of a pharmacogenomics approach to decrease incidence of vincristine-associated peripheral neuropathy in pediatric oncology patients

  • Elizabeth Sokol, MD, and Angela Waanders, MD
  • Ann & Robert H. Lurie Children’s Hospital of Chicago
  • This study seeks to genetically stratify (and ultimately protect) pediatric cancer patients who may experience enhanced toxicity from a commonly used chemotherapeutic agent – vincristine.

By providing researchers with both seed funding and access to critical networks, THRIVE will enhance the visibility of the patient need, the value of the research, and the reasons that larger funding entities might elect to incorporate these research streams into future funding priorities. Click here to learn more about grant guidelines, the application process, and selection process.